Bendamustine: New perspective for an old drug in lymphoproliferative disorders

Expert Review of Hematology

Volumn 3, Issue 2, 2010, Pages 131-148

  Montillo, Marco ^a   Ricci, Francesca ^a   Tedeschi, Alessandra ^a   Vismara, Eleonora ^a   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Bendamustine; Chemotherapy; Chronic lymphocytic leukemia; Hodgkin lymhoma; Immune chemotherapy lymphoproliferative disorders; Monoclonal antibodies; Non Hodgkin lymphoma

Indexed keywords

ALPHA INTERFERON; ANTIANEMIC AGENT; BENDAMUSTINE; BENZIMIDAZOLE; BLEOMYCIN; BORTEZOMIB; CARMUSTINE; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BACKACHE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CROSS RESISTANCE; CYTOSTASIS; DIARRHEA; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG BINDING; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FIRST PASS EFFECT; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HODGKIN DISEASE; HUMAN; HYPOTENSION; IMMUNOCYTOMA; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHOCYTOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; REMISSION; REVIEW; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VALIDATION STUDY; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; NITROGEN MUSTARD COMPOUNDS;

EID: 77953441848     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.7     Document Type: Review

References (75)

1. Ozegowski W, Krebs D. IMET 3393. g(1-methyl-5-bis-(b-chloräthyl)- amino-benzimidazolyl(2)-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste. Zbl. Pharm. 110, 1013-1019 (1971).
2. Woolley DW. Some biological effects produced by benzimidazole and their reversal by purines. J. Biol. Chem. 152, 225-232 (1944).
3. Hirschberg E, Gellhorn A, Gump WS. Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chlorethyl) aminomethyl] benzimidazole and of other 2-chlorethyl compounds. Cancer Res. 17, 904-910 (1957).
4. Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim. Biophys. Acta 287, 386-389 (1972).
5. Preiss R, Sohr R, Matthias M, Brockmann B, Huller H. The pharmacokinetics of bendamustine (Cytostasan) in humans. Pharmazie 40, 782-784 (1985).
6. Matthias M, Preiss R, Sohr R, Possinger K. Pharmacokinetics of bendamustine in patients with malignant tumors. Proc. Am. Soc. Clin. Oncol. 14 (1995) (Abstract 1476).
7. Haase D, Preiss R, Sohr R. Untersuchungen zur plasmaeiweibetabindung von bendamustin (Cytostasan) und ambazon. Z. Klin. Med. 45, 1267-1272 (1990).
8. Wohlrabe K, Jungstand W, Gutsche W. Prüfung von IMET 3393 auf die zytostatische Wirksamkeit bei oraler Applikation. Zbl. Pharm. 110, 1045-1048 (1971).
9. Fichtner I, Arndt D, Reszka R. Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, Cytostasan) encapsulated in liposomes in different murine tumor models. J. Microencapsul. 3, 77-87 (1986).
10. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin. Oncol. 29(4 Suppl. 13), 4-11 (2002).
11. Bremer K, Roth W. Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas. Tumor Diagn. Ther. 17(1), 1-6 (1996).
12. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7(4), 415-421 (1996).
13. Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 14(1), 309-317 (2008).
14. Hesse G, Schulze W, Wachtel E. Zur methodik der bestimmung alkylierender aktivitäten von N-losten mit nitrobezylpyridin (NBP) in biologischem material. Pharmazie 36, 609-612 (1981).
15. Staib P, Schinkothe T, Dimski T et al. In vitro modulation of ara-CTP accumulation in fresh AML cells by bendamustine in comparison with fludarabine, 2-CDA and gemcitabine. Blood (ASH Annual Meeting Abstracts) 94, (1999) (Abstract 63).
16. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 12(9), 725-729 (2001).
17. Bremer K. High rates of long lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J. Cancer Res. Clin. Oncol. 128(11), 603-609 (2002).
18. Kahl BS, Bartlett NL, Leonard JP et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 116(1), 106-114 (2010).
19. Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a Phase II multicenter, single agent study. J. Clin. Oncol. 26(2), 204-210 (2008).
20. Heck HK, Preiss JM, Schmidt P. Bendamustine (B) and mitoxantron (M) in the treatment of low-grade non-Hodgkin's lymphoma (MHL). J. Cancer Res. Clin. Oncol. 124(Suppl.), (1998) (Abstract R147).
21. Preiss J, Heck HK, Schmidt P. Bendamustine in the therapy of low grade malignant lymphomas. Eur. J. Cancer 35(Suppl. 4), (1999) (Abstract 1352).
22. Nickenig C, Emmerich B, Reiser M, Abenhardt W, Hiddemann W, Dreyling MH. Mitoxantrone/ bendamustine/prednisolone (MBP) in indolent lymphomas - clinical results of a Phase I/II study. Ann. Oncol. 13(Suppl. 2), (2002) (Abstract 503).
23. König U, Junghass C, Decker S et al. Response of refractory and relapsed low grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia to dexa- BID, a bendamustine hydrochloride-containing regimen. Ann. Oncol. 10(Suppl. 3), (1999) (Abstract 132).
24. Ruffert K. Therapy of low grade non- Hodgkin's lymphoma (NHL) with bendamustine and oral etoposide. Ann. Oncol. 10(Suppl. 3), (1999) (Abstract 125).
25. Kaempfe D, Rohrberg R. CyMEP-A useful salvage regimen for treatment of relapsed or refractory low-grade-lymphomas. Proceedings of 18th International Congress of Chemotherapy. (1993) (Abstract 1216).
26. Chow KU, Boehrer S, Geduldig K et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 86, 485-493 (2001).
27. Gnad M, Reichle A, Andreesen R, Bross K. Therapy of low-grade non-Hodgkin's lymphoma (NHL) with fludarabine and bendamustine. Onkologie 22(Suppl. 1), (1999) (Abstract 0637).
28. Koenigsmann M, Knauf WUK, Herold M, Wiermann MW, Bartsch R, Alfmann M. Therapy of low-grade lymphoma at relapse with fludarabin and bendamustin - a clinical Phase I/II study. Hematol. J. 1(Suppl. 1), (2001) (Abstract 519).
29. Ruffert K, Jahn H, Syrbe G et al. Cytostasan (bendamustine) as an alternative therapeutic approach to treat malignant non-Hodgkin's lymphoma. Z. Klin. Med. 44 (8), 671-674 (1989).
30. Kath R, Blumenstengel K, Fricke HJ, Peters HD, Hoffken K. Bendamustin, vincristin, prednisolon (BOP) in der therapie von fortgeschrittenen niedrig malignen non-Hodgkin-lymphomen. Dtsch. Med. Wschr. 126, 198-202 (2001).
31. Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87, 33-43 (2002)
32. Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non Hodgkin's lymphoma. J. Clin. Oncol. 23(15), 3383-3389 (2005).
33. Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J. Clin. Oncol. 26(27), 4473-9447 (2008).
34. Rummel MJ, Heine K, Bodenstein H et al. Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients. J. Clin. Oncol. 26(Suppl.), (2008) (Abstract 8572).
35. Weide R, Pandorf A, Heymanns J, Köppler H. Bendamustine/ mitoxantrone/ rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk. Lymphoma 45(5), 2445-2449 (2004).
36. Weide R, Hess G, Köppler H et al. High anti-lymphoma activity of bendamustine/ mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter Phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk. Lymphoma 48(7), 1299-1306 (2007).
37. Kirchner H, Gaede B, Steinhauer EU, Sosada M. Combined fludarabine, bendamustine and rituximab for relapses low grade malignant non-Hodgkin's lymphoma (NHL). Hematol. J. 1(Suppl. 1), (2001) (Abstract 533).
38. Moosmann P, Heizmann M, Kotrubczik N, Wernli M, Bargetzi M. Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leuk. Lymphoma 51(1), 149-152 (2010).
39. Matous J, Letzer J, Rosen P et al. Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref ) follicular lymphoma (FL): dose-finding results of the VERTICAL study. ASCO Meeting Abstracts (2009) (Abstract 8550).
40. Fowler N, Kahl BS, Rosen P et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the Phase 2 VERTICAL study. Blood (ASH Annual Meeting Abstracts) 114, (2009) (Abstract 933).
41. Friedberg JW, Vose JM, Kelly JL et al. Bendamustine, bortezomib and rituximab in patients (pts) with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter Phase II clinical trial. Blood (ASH Annual Meeting Abstracts) 114, (2009) (Abstract 924).
42. Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised Phase III trial (OSHO#19). J. Cancer Res. Clin. Oncol. 132(2), 105-112 (2006).
43. Burchardt CA, Brugger W, Maschmeyer G et al. Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. results from the Phase III study of B-R vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 114, (2009) (Abstract 2679).
44. Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to chop plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany) Blood (ASH Annual Meeting Abstracts). 114, (2009) (Abstract 405).
45. Kroetki G. Daoud A, Herold M, Willgereroth C, Scheibner K, Franke A. Preliminary results of a multi-drug chemotherapy in high grade malignant non Hodgkin lymphomas. Ann. Hematol. 67(Suppl.), (1993) (Abstract 275).
46. Kahl C, Herold M, Florschuetz A, Mueller G, Arland M, Leuner S. Bendmustine (BMMP) protocol for the treatment of refractory or relapsed high-grade non-Hodgkin's lymphoma (NHL) of advanced disease. Onkologie 20, (1997) (Abstract 552).
47. Vacirca J. Bendamustine Combined with rituximab for relapsed or refractory diffuse large b-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 114, (2009) (Abstract 4750).
48. Weidmann E, Kim SZ, Rost A et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann. Oncol. 13(8), 1285-1289 (2002).
49. Anger G, Fink R, Fleischer J et al. Vergleichsuntersuchungen zwischen cytostatsan und cyclophosphamid bei der chronischen lymphadenose, dem plasmozytom, der lymphogranulomatose und dem bronchialkarzinom. Dtsch. Gesundheitswesen 30(27), 1280-1285 (1975).
50. Blumenstengel K, Schmalenberg H, Fricke HJ et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia (demonstrated). Onkologie 20(Suppl. 1), (1997) (Abstract 549).
51. Bremer K. Bendamustine: effective salvage chemotherapy in pretreated low-grade non Hodgkin's lymphomas. Ann. Oncol. 10(Suppl. 3), (1999) (Abstract 458).
52. Kath R, Blumenstengel K, Fricke HJ, Höffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J. Cancer Res. Clin. Oncol. 127(1), 48-54 (2001).
53. Aivado M, Becker K, Neise M, Strupp C, Losem C, Haas R. Bendamustine (B) is an efficient and well-tolerated option in the palliation of pretreated B-cell chronic lymphocytic leukemias (demonstrated). Proc. Am. Soc. Clin. Oncol. 20, (2001) (Abstract 1220).
54. Bergmann MA, Goebeler ME, Herold M et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase I/ II study of the German demonstrated study group. Haematologica 90(10), 1357-1364 (2005).
55. Lissitchkov T, Arnaudov G, Peytchev D, Merkle Kh. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J. Cancer Res. Clin. Oncol. 132(2), 99-104 (2006).
56. Medgenberg D, Balleisen L, Heit W et al. Bendamustine vs. fludarabine as second-line treatment in chronic lymphocytc leukemia. Joint ECCO 15-34TH ESMO Multidisciplinary Congress (2009) (Abstract p2210).
57. Knauf WU, Lissitchtov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27(26), 4378-4384 (2009).
58. Köppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone - a new effective treatment for advanced chronic lymphocytic leukaemia: results of a Phase I/II study. Leuk. Lymphoma 45(5), 911-913 (2004).
59. Fischer K, Stilgenbauer S, Schweighofer CD et al. The German demonstrated Study Group. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (demonstrated): a multicentre Phase II trial of the German demonstrated Study Group (GdemonstratedSG). Blood (ASH Annual Meeting Abstracts) 112, (2008) (Abstract 330).
60. Fischer K, Cramer P, Stilgenbauer S et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced demonstrated: a multicenter Phase II trial of the German demonstrated Study Group (GdemonstratedSG). Blood (ASH Annual Meeting Abstracts) 114, (2009) (Abstract 205).
61. Weide R, Mergenthaler U, Friesenhahn V et al. Bendamustine/mitoxantrone/ rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. Leuk. Lymphoma 50(9), 1468-1474 (2009).
62. Herold M, Keinert K, Anger G, Eschenburg H, Richter P, Fink R. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin's disease - results of a pilot study. Onkologie 15(6), 502-505 (1992).
63. Herold M, Keinert K, Anger G. Risk adapted combined radio and chemotherapy in Hodgkin's disease - 10-year follow-up. Onkologie 22(4), 310-313 (1999).
64. Herold M, Siebert S, Schulze A et al. Reduced combined modality treatment for Hodgkin's disease: results of a randomized multicenter trial. Leuk. Lymphoma 29(Suppl.1), (1998) (Abstract P-85).
65. Ribosepharm GmbH. Bendamustine product monograph. München, Germany, (2000)
66. Moskowitz AJ, Hamlin PA, Gerecitano J et al. Bendamustine is highly active in heavily pre-treated relapsed and refractory hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant. Blood (ASH Annual Meeting Abstracts) 114, (2009) (Abstract 720).
67. Knop S, Straka C, Haen M et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 90, 1287-1288 (2005).
68. Ponisch W, Mitrou PS, Merkle K et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized Phase III study of the East German study group of Hematology and Oncology (OSHO). J. Cancer Res. Clin. Oncol. 132, 205-212 (2006).
69. Lentzsch S, O'Sullivan A, Lalo S et al. A Phase I study of bendamustine combined with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 114, (2009) (Abstract 1856).
70. Fenk R, Michael M, Zohren F et al. Escalation therapy with bortezomib, dexamethasone, and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk. Lymphoma 48, 2345-2351 (2007).
71. Hrusovsky I, Heidtmann H-H. Combination therapy of bortezomib with low-dose bendamustine in elderly patients with advanced multiple myeloma. Blood (ASH Annual Meeting Abstracts) 106, (2005) (Abstract 5122).
72. Cheson BD, Kroll ML. Bendamustine induced neurotoxicity. Clin. Adv. Hematol. Oncol. 7(11), 743-762 (2009).
73. Hallek M, Fingerle-Rowson G, Fink AM et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (demonstrated). Blood (ASH Annual Meeting Abstracts) 112, (2008) (Abstract 325).
74. Robak T, Moiseev SI, Dmoszynska A et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (demonstrated) compared with FC alone: final results from the international randomized Phase III REACH trial. Blood (ASH Annual Meeting Abstracts) 112, (2008) (Abstract 1).
75. Cheson BD, Wendtner CM, Pieper A et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-hodgkin's lymphomas and multiple myeloma: treatment recommendations from an international consensus panel. Clin. Lymphoma Myeloma DOI: 10.3816/ CLML.2010.n.002 (2010) (Epub ahead of print)